OS Therapies (OSTX) Depreciation & Amortization (CF) (2023 - 2026)
OS Therapies' (OSTX) quarterly Depreciation & Amortization (CF) came in at $124938.0 in Q1 2026, up 17876.69% YoY from N/an in Q1 2025, and little changed on a QoQ basis from $124938.0 in Q4 2025.
OS Therapies (OSTX) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of Depreciation & Amortization (CF) data on file, last reported at $124938.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 17876.69% year-over-year to $124938.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $487328.0 (up 17429.78% YoY) and the FY2025 annual result came in at $363085.0, up 12960.61% from the prior year.
- Depreciation & Amortization (CF) held at $124938.0 in Q1 2026, from $124938.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $124938.0 in Q3 2025 to a low of $100.0 in Q1 2023.
- A 4-year average of $45002.1 and a median of $1390.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) declined 13.66% — and 2026, when it jumped 17876.69%.
- Tracing OSTX's Depreciation & Amortization (CF) over 4 years: stood at $3315.0 in 2023, then sank by 58.07% to $1390.0 in 2024, then soared by 8888.35% to $124938.0 in 2025, then changed by 0.0% to $124938.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $124938.0 (Q1 2026), $124938.0 (Q4 2025), and $124938.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | OS Therapies | 19.46 Mn | 19.46 Mn | - | 124,938.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 124,938.00 |
| Mar 31, 2026 | 124,938.00 |
| Dec 31, 2025 | 124,938.00 |
| Dec 31, 2025 | 124,938.00 |
| Sep 30, 2025 | 124,938.00 |
| Sep 30, 2025 | 124,938.00 |
| Jun 30, 2025 | 112,514.00 |
| Jun 30, 2025 | 112,514.00 |
| Mar 31, 2025 | 695.00 |
| Mar 31, 2025 | 695.00 |
| Dec 31, 2024 | 1,390.00 |
| Dec 31, 2024 | 1,390.00 |
| Jun 30, 2024 | 695.00 |
| Jun 30, 2024 | 695.00 |
| Mar 31, 2024 | 695.00 |
| Mar 31, 2024 | 695.00 |
| Sep 30, 2023 | 3,315.00 |
| Sep 30, 2023 | 3,315.00 |
| Jun 30, 2023 | 805.00 |
| Jun 30, 2023 | 805.00 |